Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir rollover study in HCV GT-1
NCT01330316Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Started Jul 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01330316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01330316.